about
Nutrient reference value: non-communicable disease endpoints--a conference reportRecommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycinOpportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacologyBiomarkers for smoking cessation
P2860
Q28078517-88AA79FF-C6E5-4B84-82A2-660EB0B0C572Q30624174-9B1E8D14-CE51-45AE-9F9F-6C55815CFF09Q33798268-5BF128C6-F30A-4C45-AD87-B6299A36B310Q35180727-618C009F-473E-475D-A101-F279C3EB21DDQ35533376-3E25860F-946C-46D6-963D-B9AB18868E66Q35681250-13558DA4-9E43-4535-90DA-35BCA4993D40Q37169216-9E808AD9-5F5D-4EC0-B261-62F07CF1FC4F
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
type
altLabel
Perspectives on Biomarker and Surrogate Endpoint Evaluation
@en
P356
P1433
P1476
Perspectives on Biomarker and Surrogate Endpoint Evaluation
@en
P356
10.17226/13038
P407
P577
2011-01-01T00:00:00Z